Mutations in canonical oncogenes such as BRAF, KRAS, PIK3CA, and ALK function as dominant molecular drivers, defining biologically distinct tumor subsets characterized by specific therapeutic liabilities [34,51]. Here, KRAS is linked to neoplasm.